2018年12月27日星期四

PDF] Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

PDF] Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

A Sabet, K Ezziddin, UF Pape, H Ahmadzadehfar… - J Nucl Med, 2013 - academia.edu
Myelosuppression may be the dose-limiting toxicity in peptide receptor radionuclide therapy
(PRRT). The aim of this study was to investigate the incidence, severity, and reversibility of
long-term hematotoxicity in a large cohort of patient undergoing PRRT with 177Lu-octreotate …


For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to >99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.

Eva He
eva@pepmic.com
Pepmic Co., Ltd
www.pepmic.com


没有评论:

发表评论